Nanobiotix (NBTX) Hisse Özeti

NBTX temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	5/6
Geçmiş Performans	0/6
Finansal Sağlık	1/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 35.6% daha düşük bir oranda işlem görüyor

Kazançların yılda 55.06% oranında artması öngörülüyor

Risk Analizi

Negatif hissedar öz sermayesi

Son 3 ayda US piyasasına kıyasla dalgalı hisse senedi fiyatı

NBTX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Nanobiotix S.A. Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Nanobiotix
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	€41.01
52 Haftanın En Yüksek Seviyesi	€57.14
52 Haftanın En Düşük Seviyesi	€3.81
Beta	0.58
1 Aylık Değişim	22.13%
3 Aylık Değişim	64.70%
1 Yıllık Değişim	1,020.86%
3 Yıllık Değişim	750.72%
5 Yıllık Değişim	139.54%
Halka arzdan bu yana değişim	141.52%

Son Haberler & Güncellemeler

Recent updates

Seeking Alpha • Oct 23

Nanobiotix S.A: Behind The Recent Momentum

Summary Nanobiotix S.A. has recently surged on strong NBTXR3 data, but its sole asset is out-licensed to Johnson & Johnson. NBTXR3 shows promise in multiple cancer indications, especially head and neck, NSCLC, and melanoma, with pivotal readouts expected in 1H26. Despite potential blockbuster royalties, NBTX's $1.1B valuation appears stretched due to limited pipeline and reliance on J&J for development. An analysis around Nanobiotix follows in the paragraphs below. Read the full article on Seeking Alpha

Seeking Alpha • Oct 18

Nanobiotix enters final agreement to restructure existing loan with EU's investment bank

French biotech Nanobiotix (NASDAQ:NBTX) on Tuesday said it had reached a final agreement with the European Investment Bank (EIB) to re-align about €30.7M in outstanding debt obligations with its expected development and commercialization timelines. The company had previously announced the agreement-in-principle with the EIB in mid-Sept. As per the newly executed final agreement, NBTX can now defer repayment of the remaining €25.3M of the loan set to be paid in two tranches up to June 2029. The restructuring agreement also includes a new milestone payment of €20M due in June 2029. U.S.-listed shares of NBTX -2.4% to $4 after hours.

Seeking Alpha • Sep 28

Nanobiotix GAAP EPS of -€0.76, revenue of €1.33M beats by €0.11M

Nanobiotix press release (NASDAQ:NBTX): 1H GAAP EPS of -€0.76. Revenue of €1.33M (+0.8% Y/Y) beats by €0.11M. Cash and Cash Equivalents: Cash and cash equivalents as of June 30, 2022, were €63.0 million, compared to €83.9 million as of December 31, 2021.

Seeking Alpha • Sep 12

Nanobiotix agrees in principle to restructure debt obligations with EU's investment bank

French biotech Nanobiotix (NASDAQ:NBTX) on Monday said it had reached an agreement in principle to restructure €30.7M in outstanding debt obligations related to its 2018 loan agreement with the European Investment Bank. NBTX said the debt restructuring was done to realign debt obligations with the company's development and commercialization timelines. The company said that execution of the amendment to the debt obligations is expected in Q4 2022 after the legal documents are finalized. "Restructuring existing debt obligations to extend the maturity date of the loan will enable Nanobiotix to drive priority development programs in 2023 by extending operating runway an additional quarter," NBTX CFO Bart Van Rhijn said in a statement. NBTX said the restructuring of the debt obligations combined with capital available through its existing equity line allows the company to extend its operating runway into Q1 2024. U.S.-listed shares of NBTX +0.2% to $4.17 in mid-day trading.

Seeking Alpha • Aug 01

French biotech Nanobiotix rebounds to post best ever 47% intraday gain

ADRs of Paris-based clinical-stage biotech Nanobiotix S.A. (NASDAQ:NBTX) recovered from a sharp selloff on Monday to record the biggest ever intraday gain thanks to strong trading volumes. Nanobiotix (NBTX) plunged nearly 30% on above-average volume to reach an all-time low on Friday. However, the stock has added ~47% on Monday, with nearly 34.4K ADRs changing hands compared to the 65-day average of ~1.1K. This quarter, Nanobiotix (NBTX) is on track to launch its first U.S. clinical trial sites in an ongoing pivotal Phase 3 trial for lead candidate NBTXR3 in head and neck squamous cell carcinoma. Its partner for the program, LianBio (LIAN) also plans to activate the first trial site and dose the first patient in Asia in H2 2022 for the candidate against the same indication.

Hissedar Getirileri

	NBTX	US Biotechs	US Pazar
7D	-20.4%	1.2%	1.1%
1Y	1,020.9%	34.6%	28.7%

Getiri vs. Endüstri: NBTX geçen yıl % 34.6 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: NBTX geçen yıl % 28.7 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is NBTX's price volatile compared to industry and market?
NBTX volatility
NBTX Average Weekly Movement	16.3%
Biotechs Industry Average Movement	10.8%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: NBTX hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.

Zaman İçindeki Volatilite: NBTX 'nin haftalık oynaklığı ( 16% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2003	100	Laurent Levy	www.nanobiotix.com

Nanobiotix S.A., kanser ve diğer karşılanmamış tıbbi ihtiyaçların tedavisi için ürün adayları geliştirmeye odaklanan klinik aşamalı bir biyoteknoloji olarak faaliyet göstermektedir. Öncü ürün adayı, yumuşak doku sarkomu, baş ve boyun, karaciğer, prostat, pankreas, özofagus, rektum ve küçük hücreli dışı akciğer kanserinin tedavisinde kullanılan kristal hafniyum oksit nanopartiküllerinin steril bir sulu süspansiyonu olan NBTXR3'tür. Şirket, NBTXR3'ü Çin, Güney Kore, Singapur ve Tayland'da geliştirmek ve ticarileştirmek için Lian Oncology Limited ile bir ortaklığa sahiptir.

Nanobiotix S.A. Temel Bilgiler Özeti

Nanobiotix'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
NBTX temel i̇stati̇sti̇kler
Piyasa değeri	US$2.05b
Kazançlar(TTM)	-US$27.81m
Gelir(TTM)	US$37.83m

54.2x

P/S Oranı

-73.8x

F/K Oranı

NBTX aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
NBTX gelir tablosu (TTM)
Gelir	€32.59m
Gelir Maliyeti	€0
Brüt Kâr	€32.59m
Diğer Giderler	€56.55m
Kazançlar	-€23.96m

Son Raporlanan Kazançlar

Dec 31, 2025

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.49
Brüt Marj	100.00%
Net Kâr Marjı	-73.52%
Borç/Özkaynak Oranı	-109.2%

NBTX uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/24 17:19
Gün Sonu Hisse Fiyatı	2026/05/22 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Nanobiotix S.A. 19 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Philippa Gardner	Edison Investment Research
Jonathan Miller	Evercore ISI
Emmanuel Parot	Gilbert Dupont

Nanobiotix (NBTX) Hisse Özeti

Ödüller

Risk Analizi

Nanobiotix S.A. Rakipler

Nurix Therapeutics

Intellia Therapeutics

Vericel

Recursion Pharmaceuticals

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of €85 million.

Nanobiotix S.A. has filed a Follow-on Equity Offering in the amount of €75 million.

Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study

Nanobiotix S.A., Annual General Meeting, Jun 09, 2026

Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for Lnp-Delivered Dna Immunotherapy After Pre-Treatment with Nanoprimer Technology

Nanobiotix Presents First Data From Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) In Stage 3 Inoperable Lung Cancer

Recent updates

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of €85 million.

Nanobiotix S.A. has filed a Follow-on Equity Offering in the amount of €75 million.

Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study

Nanobiotix S.A., Annual General Meeting, Jun 09, 2026

Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for Lnp-Delivered Dna Immunotherapy After Pre-Treatment with Nanoprimer Technology

Nanobiotix Presents First Data From Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) In Stage 3 Inoperable Lung Cancer

Nanobiotix S.A. to Report Q4, 2025 Results on Mar 31, 2026

Nanobiotix S.A: Behind The Recent Momentum

Nanobiotix S.A. Announces First Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients with Esophageal Cancer

Nanobiotix Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)

Nanobiotix Announces Full Results from Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

Nanobiotix Announces Presentation of Full Results from Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by Conference Call

Nanobiotix S.A., Annual General Meeting, May 19, 2025

Nanobiotix S.A. to Report Q4, 2024 Results on Apr 02, 2025

Nanobiotix Announces First Patient Dosed in A New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients with Stage 3 Unresectable Non-Small Cell Lung Cancer

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

Nanobiotix S.A. to Report Q1, 2024 Results on May 22, 2024

Nanobiotix Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating Nbtxr3 for Patients with Stage Three Lung Cancer

Nanobiotix S.A. to Report Q4, 2023 Results on Apr 24, 2024

Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. to Report Q3, 2023 Results on Nov 13, 2023

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of $29.288592 million.

Nanobiotix S.A. has filed a Follow-on Equity Offering in the amount of $30 million.

Nanobiotix S.A. announced that it expects to receive $25 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. Announces Updated Preliminary Results from Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis from Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Nanobiotix S.A. Announces New Clinical Data from Phase 1 Study Evaluating Radiotherapy-Activated Nbtxr3 for Patients with Pancreatic Ductal Adenocarcinoma

Nanobiotix S.A. to Report First Half, 2023 Results on Sep 26, 2023

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

Nanobiotix S.A. Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers

Nanobiotix S.A., Annual General Meeting, Jun 27, 2023